Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Ind-Swift surges on talk of atorvastatin API supply deal with Ranbaxy

This article was originally published in Scrip

Executive Summary

Shares of Ind-Swift Laboratories were on a roll on Indian bourses on 14 September following reports that the firm was in discussions to supply atorvastatin active pharmaceutical ingredient (API) to Ranbaxy for the latter's cut-price generic version of Pfizer's Lipitor. A US launch of Ranbaxy's product is expected at the end of November this year.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts